Detalhe da pesquisa
1.
A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth.
Genes Dev
; 29(5): 483-8, 2015 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25737277
2.
Targeting a lineage-specific PI3KÉ£-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule.
Nat Cancer
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38816660
3.
Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.
J Pathol
; 227(1): 118-29, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22069124
4.
A multiparametric niche-like drug screening platform in acute myeloid leukemia.
Blood Cancer J
; 12(6): 95, 2022 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35750691
5.
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Nat Cancer
; 3(7): 837-851, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35668193
6.
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.
Leukemia
; 36(6): 1585-1595, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35474100
7.
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.
Sci Transl Med
; 13(587)2021 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33790022
8.
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.
Cancer Discov
; 10(12): 1894-1911, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32826232
9.
To be or not to be cell autonomous? Autophagy says both.
Essays Biochem
; 61(6): 649-661, 2017 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29233875
10.
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Nat Med
; 23(3): 301-313, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28191887
11.
Targeting MTHFD2 in acute myeloid leukemia.
J Exp Med
; 213(7): 1285-306, 2016 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27325891
12.
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.
J Exp Med
; 213(9): 1705-22, 2016 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27455953
13.
Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis.
Nat Commun
; 6: 6993, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25925867
14.
SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Cancer Cell
; 25(2): 226-42, 2014 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24525236
15.
When autophagy meets cancer through p62/SQSTM1.
Am J Cancer Res
; 2(4): 397-413, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22860231
16.
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
PLoS One
; 7(7): e40378, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22911700
17.
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.
J Mol Cell Biol
; 4(4): 207-20, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22467682
18.
The p53/p21Cip1/âWaf1 pathway mediates the effects of SPARC on melanoma cell cycle progression.
Pigment Cell Melanoma Res
; 24(1): 219-32, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20955243
19.
Mechanism of action of the multikinase inhibitor Foretinib.
Cell Cycle
; 10(23): 4138-48, 2011 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22101270
20.
Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.
Cancer Res
; 70(3): 1042-52, 2010 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20103647